BOSTON, April 30, 2019 /PRNewswire/ -- OM1, a leading health outcomes, data and technology company today announced that its rheumatology registries, which track hundreds of thousands of patients longitudinally throughout the United States, are now available for direct licensing as well as studies and advanced analytics. The registries include:
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Giant Cell Arteritis
- Systemic Scleroderma
- Juvenile Idiopathic Arthritis
- Ankylosing Spondylitis
- Hidradenitis Suppurativa
The OM1 registries are continually enrolling and updating and include patient reported outcomes as well as linkage to other data sources. These specialized clinical databases are used for streamlining research, understanding treatments and improving patient outcomes for life sciences companies and providers.
"Understanding these conditions at a deeper level is critical to every stakeholder. We are proud to be advancing research and improving care through better, more complete and timely data," said Dr. Richard Gliklich, CEO of OM1. "Enabling our customers to have direct access to research-grade data will help advance care even more rapidly."
The registry data is available for licensing and through OM1's advanced data visualization and analytics tools. For more information, visit www.om1.com.
Head of Marketing, OM1
OM1 is a leading health outcomes and technology company leveraging big clinical data and AI to better understand, compare, and predict patient outcomes. OM1's real world evidence platform, clinical registries and AI technologies enable clients to accelerate research, measure and benchmark health outcomes and to personalize patient care.